

## **Amendment to the Claims**

### **Listing of claims:**

**Claim 1 (canceled):** An axon growth stimulation kit comprising  
a first container means for containing a flowable carrier component or two or more  
separate components capable once intermingled of forming a flowable carrier  
component, said flowable carrier components each being capable of forming a  
therapeutically acceptable matrix in vivo at a nerve lesion site and  
a second container means for containing a therapeutically active agent for facilitating  
axon growth at the lesion site  
wherein said therapeutically active agent is releasable from said in vivo matrix into  
the adjacent external environment.

**Claim 2 (canceled):** An axon growth stimulation kit as defined in claim 1 comprising  
means for dispersing the therapeutically active agent in said flowable carrier  
component so as to form a flowable axon growth stimulation composition  
and  
means for delivering the flowable axon growth stimulation composition to the lesion  
site.

**Claim 3 (withdrawn):** An axon growth stimulation kit as defined in claim 1 wherein  
said therapeutically acceptable matrix is a collagen matrix.

**Claim 4 (canceled):** An axon growth stimulation kit as defined in claim 1  
wherein said therapeutically acceptable matrix is a fibrin matrix.

**Claim 5 (canceled):** A biocompatible composition comprising: (i) at least one  
supplement selected from the group consisting of therapeutically active agents for  
facilitating axon growth; and (ii) a flowable carrier component capable of forming a  
therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said  
supplement is releasable from said matrix into the adjacent external environment.

**Claim 6 (withdrawn):** A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a collagen matrix.

**Claim 7 (canceled):** A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a fibrin matrix.

**Claim 8 (withdrawn):** A method for the preparation of a flowable biocompatible composition comprising admixing (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the adjacent external environment.

**Claim 9 (withdrawn):** A method as defined in claim 8 wherein said therapeutically acceptable matrix is a collagen matrix.

**Claim 10 (withdrawn):** A method as defined in claim 8 wherein said therapeutically acceptable matrix is a fibrin matrix.

**Claim 11 (new) :**

An axon sprouting stimulation kit comprising

    a first container means having a first matrix forming element, and;

    a second container means having a second matrix forming element,

said first and second matrix forming elements being capable once intermingled of forming a flowable carrier component and said first and second matrix forming elements further being capable of forming a therapeutically acceptable in vivo fibrin matrix at a nerve lesion site,

and whereby at least one of said first and second container means further comprises a therapeutically active agent selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting at said lesion site and wherein said therapeutically active agent is releasable from said therapeutically acceptable in vivo fibrin matrix

into an adjacent external environment.

**Claim 12 (new):** An axon sprouting stimulation kit as defined in claim 11 comprising means for dispersing the therapeutically active agent in said flowable carrier component so as to form a flowable axon sprouting stimulation composition and means for delivering the flowable axon sprouting stimulation composition to the lesion site.

**Claim 13 (new)** An axon sprouting stimulation kit as defined in claim 11, wherein C3 is selected from the group consisting of an ADP-ribosyl transferase C3 derived from *Clostridium botulinum*, a C3 analogue capable of inactivating a Rho GTPase and a recombinant ADP-ribosyl transferase C3.

**Claim 14 (new):** A biocompatible composition comprising: (i) a therapeutically active agent selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting, and (ii) a first matrix forming element capable of forming a flowable carrier component once intermingled with a second matrix forming element, and said first and second matrix forming elements further being capable of forming a therapeutically acceptable in vivo fibrin matrix at a nerve lesion site, wherein said therapeutically active agent is releasable from said in vivo fibrin matrix into an adjacent external environment.

**Claim 15 (new)** A biocompatible composition as defined in claim 14, wherein C3 is selected from the group consisting of an ADP-ribosyl transferase C3 derived from *Clostridium botulinum*, a C3 analogue capable of inactivating a Rho GTPase and a recombinant ADP-ribosyl transferase C3.

**Claim 16 (new)** An axon sprouting stimulation kit comprising

- a first container means having a first matrix forming element, and;
- a second container means having a second matrix forming element, said first and second matrix forming elements being capable once intermingled of

forming a flowable carrier component and said first and second matrix forming elements further being capable of forming a therapeutically acceptable in vivo fibrin matrix at a nerve lesion site, and;  
-a third container means comprising a therapeutically active agent selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting at said lesion site,

wherein said therapeutically active agent is releasable from said therapeutically acceptable in vivo fibrin matrix into an adjacent external environment.

**Claim 17 (new):** An axon sprouting stimulation kit as defined in claim 16 comprising means for dispersing the therapeutically active agent in said flowable carrier component so as to form a flowable axon sprouting stimulation composition and means for delivering the flowable axon sprouting stimulation composition to the lesion site.

**Claim 18 (new)** An axon sprouting stimulation kit as defined in claim 16, wherein C3 is selected from the group consisting of an ADP-ribosyl transferase C3 derived from *Clostridium botulinum*, a C3 analogue capable of inactivating a Rho GTPase and a recombinant ADP-ribosyl transferase C3.

### **Amendments to the Sequence Listing**

The attached substitute paper copy of "Sequence Listing" includes changes which have been made to the "Sequence Listing" (paper copy and computer readable form) and reflect the amendments carried out herein with respect to the amino acid sequence disclosed at page 43, lines 6 to 10.

This substitute paper copy replaces the "Sequence Listing" sheets found at pages 46 to 51 of the present application. A replacement computer readable form of the amended "Sequence Listing" is also being presented herein in accordance with the requirements of 37 CFR 1.824.

Attachment:           Substitute paper copy- Sequence Listing  
                          Annotated sheets showing changes-Sequence Listing  
                          Replacement computer readable form of the Sequence Listing